Delivered to your Trust or directly to your Patient:

How to order Kinpeygo®

Kinpeygo®

Kinpeygo® – the first and only disease-modifying treatment approved across Europe and by NICE specifically for use in IgA nephropathy1,2

Kinpeygo® is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with urine protein-to-creatinine ratio (UPCR) ≥ 1.5g/gram

Prescribing Information can be found here
Adverse Event reporting information can be found in the footer

Find out more about Kinpeygo®

Request a visit from our Medical Science Liaison Team or Healthcare Partnership Manager Team

Request a visit

How to order Kinpeygo®

Order via HealthNet Homecare for delivery to your Trust or direct to your patient.

How to order

Clinical Resource:

 

Kinpeygo®
Formulary Guide

Click to view

Kinpeygo®
NICE Guidance

Click to view

Kinpeygo®
Pharmacy Leaflet

Click to view

Kinpeygo®
Clinician Leaflet

Click to view

Educational Webinars

View webinars

Kinpeygo® Patient Support Leaflet

Click to view

Visit the Kinpeygo® Patient Website

Click to view

Let’s stay connected!

Want to be the first to hear about the products, services and educational resources we offer, including invitations to webinars and events?

Sign up here

References

1. European public assessment report (EPAR) Kinpeygo. EMA/570757/2022, last revised 05/2022. 2. Overview | Targeted-release budesonide for treating primary IgA nephropathy | Guidance | NICE. https://www.nice.org.uk/guidance/ta937 (Published: 20 December 2023).

Information

For information on our products please visit EMC, https://www.medicines.org.uk/emc/ and search the product for a Summary of Product Characteristics

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.

UK-MULT-122e(3) | Date of Preparation: November 2024

This site is intended to provide information to Healthcare Professionals on Thornton & Ross products.

I am a UK Healthcare Professional

Yes     No

The information on our Healthcare Professional Website is solely intended for UK Healthcare Professionals and contains promotional information. Click here to return to our main public site.

For information on our products please visit EMC and search the product for a Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.